CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 251 enrolled
Drug / intervention
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03031912
NCT03031912Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents

Canadian Immunization Research Network·interventional·Posted Jan 26, 2017·Updated Jan 12, 2026

In Brief

A Phase 2 clinical trial evaluating V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine and Saline for Ebola. Completed, enrolled 251 participants across 1 site.

Detailed Summary

This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices. The study will take place at 2 Canadian sites (Centre Hospitalier de l'Université de Montréal and Ottawa General Hospital) and 2 African sites (Centre MURAZ, Burkina Faso and Centre Hospitalier National Aristide Le Dantec, Dakar, Senegal). The Duration of Study: 365 days for each participant not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola
CountriesCanada
CollaboratorsMerck Sharp & Dohme LLC, International Development Research Centre, Canada, Dalhousie University, Université de Montréal, Coalition for Epidemic Preparedness Innovations, University of Ottawa, Centre Muraz, Institute for Health Research - Epidemiological Surveillance and Training (IRESSEF)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 26, 2017
Enrollment StartAug 1, 2017
Primary CompletionMar 3, 2023
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.4 years ago

Interventions

V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccinebiological

The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.

Salineother

Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.